Drug Profile
ISS-cat allergen conjugate - Dynavax
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Class
- Mechanism of Action Immunosuppressants; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergy in USA
- 16 Apr 2008 Preclinical development is ongoing
- 30 Jul 2007 Preclinical trials in Allergy in USA (unspecified route)